Endpoints News· Ayisha Sharma·· 1 天前AI 评分50
计提 19 亿美元减值后，Novartis 仍坚持对 Avidity 的 120 亿美元押注
After $1.9B impairment hit, Novartis stands by $12B bet on Avidity
AI 导读
Novartis CEO Vas Narasimhan 表示，公司以 120 亿美元收购 Avidity Biosciences 的交易"仍完全按计划推进"。此前公司披露了一笔 19 亿美元的减值。
正文 · 原文
Novartis’ $12 billion acquisition of Avidity Biosciences “remains absolutely on track,” CEO Vas Narasimhan said, after the company disclosed a $1.9 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news